Reversible cerebral vasoconstriction syndrome associated with fingolimod treatment in relapsing-remitting multiple sclerosis three months after childbirth

Mult Scler. 2015 Oct;21(11):1473-5. doi: 10.1177/1352458515600249. Epub 2015 Aug 17.


Reversible cerebral vasoconstriction syndrome (RCVS) is characterized by acute thunderclap headache, evidence of vasoconstriction in conventional angiography or magnetic resonance angiography and reversibility of these phenomena within 12 weeks. Some triggering factors, for example drugs such as selective serotonin reuptake inhibitors, sumatriptan, tacrolimus, cyclophosphamide and cocaine, or states such as pregnancy, puerperium or migraine have been described. We describe the case of a 29-year-old woman with RCVS associated with fingolimod three months after childbirth. This case represents the first report of RCVS in fingolimod treatment.

Keywords: Reversible cerebral vasoconstriction syndrome; fingolimod; trigger.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Cerebrovascular Disorders / chemically induced*
  • Female
  • Fingolimod Hydrochloride / adverse effects*
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Parturition*
  • Pregnancy
  • Syndrome
  • Vasoconstriction / drug effects*


  • Immunosuppressive Agents
  • Fingolimod Hydrochloride